We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

News in brief

Pharmaceutical Law Insight

News in brief

AstraZeneca settles generic Entocort suit UNITED STATES Anglo-Swedish drug maker AstraZeneca has reached a settlement with Teva Pharmaceuticals over the marketing of a generic copy of AstraZeneca’s anti-inflammatory drug Entocort (budesonide). Under the terms of the agreement, Teva will be able to sell its budesonide in the US from 15 February 2012, subject to regulatory approval ‘or earlier in certain circumstances’. No financial details have been disclosed.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?


Request a trial Find out more